Trial reportBMJ global health2025
Effect of azithromycin on post-discharge growth in Kenyan children.
Trial report in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02414399 (Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionChildren discharged following hospitalisation for acute illnesses in low- and middle-income settings are at increased risk of poor growth, particularly linear growth faltering. We aimed to determine the effect of azithromycin administered at hospital discharge on post-discharge growth.
methodsUsing data from the Toto Bora Trial (NCT02414399), a double-blind, placebo-controlled randomised trial of a 5-day course of azithromycin in Kenyan children aged 1-59 months, we assessed differences in mean monthly change in growth (height-for-age z-score (HAZ), weight-for-height z-score (WHZ), weight-for-age z-score (WAZ)) in the 6 months following hospital discharge.
resultsThis analysis included 1276 children who survived to 6 months post-discharge (640 randomised to azithromycin and 636 to placebo). At discharge, 285 (22%) of children were stunted, 64 (5%) were wasted and 156 (12%) were underweight. There was no difference in 6-month post-discharge growth (mean difference: HAZ, 0.010 (95% CI -0.005 to 0.025); WAZ, 0.003 (95% CI -0.013 to 0.019); WHZ, -0.003 (95% CI -0.025, 0.019)) between treatment groups. Further, no differences in mean monthly change in HAZ, WAZ or WHZ were observed between randomisation groups when stratified by age, nutritional status at discharge or discharge diagnosis. Mean monthly change in HAZ declined among all children in the 6 months post-discharge, irrespective of the treatment group (azithromycin group: -0.038 (95% CI -0.049 to -0.028); placebo group: -0.048 (95% CI -0.059 to -0.038). Mean monthly change in WAZ did not differ significantly by treatment group (0.025 (95% CI 0.013 to 0.037) in the azithromycin group and 0.022 (95% CI 0.011 to 0.033) in placebo (p=0.688)). Monthly WAZ and WHZ gains were similar in both groups, with greater weight gains among older children (6-11, 12-23, 24-59 months).
conclusionWe did not observe statistically significant improvements in post-discharge growth among children receiving azithromycin at hospital discharge. TRIAL REGISTRATION NUMBER: NCT02414399.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.